<DOC>
	<DOCNO>NCT02438995</DOCNO>
	<brief_summary>This open-label , non-randomized , two arm , Phase I research study superselective intraarterial Cetuximab ( Erbitux ) without radiation therapy treatment recurrent unresectable squamous cell carcinoma head neck ( HNSCC ) .</brief_summary>
	<brief_title>Super-Selective Intraarterial Infusion Cetuximab ( Erbitux ) With Without Radiation Therapy Treatment Unresectable Recurrent Squamous Cell Carcinoma Head Neck</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>1 . Male female patient ≥18 year age . 2 . Patients document diagnosis recurrent head neck squamous cell cancer ( squamous cell carcinoma , include nasopharyngeal cancer , adenoid cystic carcinoma ) . Patients must least one confirm evaluable tumor site . * The recurrence must bidimensional measurement clinical examination CT/MRI/PET scan . A confirmed recurrence site may also biopsyproven 3 . Tumor Recurrence surgically unresectable 4 . Patients must Karnofsky performance status ≥70 % ( equivalent ECOG level 02 ) ( see Appendix Performance Status Evaluation ) expect survival ≥ three month . 5 . Patients must adequate hematologic reserve WBC≥3000/mm3 , absolute neutrophil ≥1500/mm3 platelet ≥100,000/ mm3 . Patients Coumadin must platelet count ≥150,000/ mm3 6 . Preenrollment chemistry parameter must show : bilirubin &lt; 1.5X institutional upper limit normal ( IUNL ) ; AST ALT &lt; 2.5X IUNL creatinine &lt; 1.5X IUNL . 7 . Preenrollment coagulation parameter ( PT PTT ) must ≤1.5X IUNL . 8 . Patients must agree use medically effective method contraception period three month treatment period . A pregnancy test perform premenopausal female childbearing potential immediately prior entry research study . 9 . Patients must able understand give write informed consent . Informed consent must obtain time patient screening . 10 . Patients refuse surgery . 1 . Women pregnant lactating . 2 . Women childbearing potential fertile men inform potential risk procreation participate research trial advise must use effective contraception period three month treatment period . 3 . Patients significant intercurrent medical psychiatric condition would place increased risk affect ability receive comply treatment posttreatment clinical monitoring . 4 . Preexisting cardiac respiratory disorder 5 . Unrelated malignancy within 3 year 6 . History hypersensitivity reaction EGFR inhibitor 7 . Metastatic disease 8 . Less 6 month prior Radiation Therapy ( Arm 1 ) 9 . Previous exposure Cetuximab</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>